<br>蜂毒肽的免疫调节活性和生物医学应用及其最新进展,Archiv der Pharmazie

当前位置： X-MOL 学术 › Arch. Pharm. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

蜂毒肽的免疫调节活性和生物医学应用及其最新进展
Archiv der Pharmazie ( IF 4.3 ) Pub Date : 2024-01-22 , DOI: 10.1002/ardp.202300569
Zohreh Jafari ₁ , Sahar Sadeghi ₁ , Mahsa Mirzarazi Dehaghi ₁ , Ashkan Bigham _{2,

3} , Shokouh Honarmand ₄ , Afsaneh Tavasoli ₅ , Mostafa Haji Molla Hoseini _{6,

7} , Rajender S Varma ₈

Affiliation

蜂毒肽 (MLT) 是一种含有 26 个氨基酸的肽，是蜂毒的关键成分。它占蜂毒干重的 40%–60%，是蜂毒的主要定价指标，也是引起疼痛的因素。从蜂毒中提取的 MLT 的独特性质使其成为制药行业非常有价值的活性成分，因为这种阳离子和两亲性肽在多种生物过程中对人类健康具有有益的影响。它能够强烈冲击细胞膜并表现出具有抗癌特性的溶血活性。然而，MLT 的临床应用因其严重的溶血活性而受到限制，这对治疗用途提出了挑战。通过采用更有效的机制，例如修改 MLT 序列、基因工程和纳米递送系统，预计可以克服 MLT 带来的限制，从而使其在治疗环境中得到更广泛的应用。这篇综述概述了 MLT 纳米递送系统和表达 MLT 的基因工程细胞的最新进展，并概述了 MLTMLT 平台的现状以及未来面临的挑战。重点是探索这些方法如何克服与 MLT 溶血活性相关的限制，并提高其靶向癌细胞的选择性和功效。这些进步有望创建基于 MLT 的创新和增强的癌症治疗方法。

"点击查看英文标题和摘要"

Immunomodulatory activities and biomedical applications of melittin and its recent advances

Melittin (MLT), a peptide containing 26 amino acids, is a key constituent of bee venom. It comprises ∼40%–60% of the venom's dry weight and is the main pricing index for bee venom, being the causative factor of pain. The unique properties of MLT extracted from bee venom have made it a very valuable active ingredient in the pharmaceutical industry as this cationic and amphipathic peptide has propitious effects on human health in diverse biological processes. It has the ability to strongly impact the membranes of cells and display hemolytic activity with anticancer characteristics. However, the clinical application of MLT has been limited by its severe hemolytic activity, which poses a challenge for therapeutic use. By employing more efficient mechanisms, such as modifying the MLT sequence, genetic engineering, and nano-delivery systems, it is anticipated that the limitations posed by MLT can be overcome, thereby enabling its wider application in therapeutic contexts. This review has outlined recent advancements in MLT's nano-delivery systems and genetically engineered cells expressing MLT and provided an overview of where the MLTMLT's platforms are and where they will go in the future with the challenges ahead. The focus is on exploring how these approaches can overcome the limitations associated with MLT's hemolytic activity and improve its selectivity and efficacy in targeting cancer cells. These advancements hold promise for the creation of innovative and enhanced therapeutic approaches based on MLT for the treatment of cancer.

更新日期：2024-01-22

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南